Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Willson
S Lawrence

Showing results (1401-1410 of 1,504) with videos related to

Pageof 151
Sort By:
Cancer Discovery|February 22, 2024
Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC ParalogsShreoshi Pal Choudhuri, Luc Girard, Jun Yi Stanley Lim, et al.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 14, 2020
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profileKrinio Giannikou, Zachary Zhu, Jaegil Kim, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2012
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2Heidi Greulich, Bethany Kaplan, Philipp Mertins, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
The Lancet. HIV|October 6, 2023
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation studySayoki Mfinanga, Cecilia Kanyama, Charles Kouanfack, et al.
Genome Biology|February 11, 2020
A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cellsSooncheol Lee, Douglas Micalizzi, Samuel S Truesdell, et al.
Cancer Discovery|August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung CancerAnna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
The New England Journal of Medicine|December 14, 2011
SF3B1 and other novel cancer genes in chronic lymphocytic leukemiaLili Wang, Michael S Lawrence, Youzhong Wan, et al.
Pageof 151

Showing results (1401-1410 of 1,504) with videos related to

Sort By:
Pageof 151
Cancer Discovery|February 22, 2024
Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC ParalogsShreoshi Pal Choudhuri, Luc Girard, Jun Yi Stanley Lim, et al.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 14, 2020
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profileKrinio Giannikou, Zachary Zhu, Jaegil Kim, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2012
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2Heidi Greulich, Bethany Kaplan, Philipp Mertins, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
The Lancet. HIV|October 6, 2023
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation studySayoki Mfinanga, Cecilia Kanyama, Charles Kouanfack, et al.
Genome Biology|February 11, 2020
A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cellsSooncheol Lee, Douglas Micalizzi, Samuel S Truesdell, et al.
Cancer Discovery|August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung CancerAnna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
The New England Journal of Medicine|December 14, 2011
SF3B1 and other novel cancer genes in chronic lymphocytic leukemiaLili Wang, Michael S Lawrence, Youzhong Wan, et al.
Pageof 151